Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.3%

1 terminated/withdrawn out of 23 trials

Success Rate

95.5%

+9.0% vs industry average

Late-Stage Pipeline

39%

9 trials in Phase 3/4

Results Transparency

10%

2 of 21 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

6(26.1%)

Phase 1

5(21.7%)

N/A

5(21.7%)

Phase 2

4(17.4%)

Phase 4

3(13.0%)

23Total

Phase 3(6)

Phase 1(5)

N/A(5)

Phase 2(4)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials

NCT01169259Phase 3Active Not Recruiting

Vitamin D and Omega-3 Trial (VITAL)

Role: collaborator

NCT03018041Phase 3Completed

The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation

Role: collaborator

NCT01813110Not ApplicableCompleted

Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation

Role: collaborator

NCT01813006Phase 3Completed

Effect of Omega-3 Fatty Acid on Endothelial Function

Role: collaborator

NCT02763514Not ApplicableCompleted

The Effects of DHA- and EPA-enriched Oils on Cognitive Function and Mood

Role: collaborator

NCT02923804Not ApplicableCompleted

Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients

Role: lead

NCT03158545Not ApplicableCompleted

26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Cerebral Blood Flow in Healthy Adults

Role: collaborator

NCT02661698Not ApplicableCompleted

Plasma Diurnal Variation in and Absorption of EPA and DHA

Role: collaborator

NCT01744067Phase 4Completed

The Effects of Omega-3 Fatty Acids in Renal Transplantation

Role: collaborator

NCT01893515Phase 2Completed

The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

Role: lead

NCT01972178Phase 2Terminated

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

Role: lead

NCT02364635Phase 1Completed

Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects

Role: lead

NCT02376608Phase 1Completed

Bioavailability of Omega-3 Food Supplement in Healthy Subjects

Role: lead

NCT02376621Phase 1Completed

Bioavailability of Omega-3 Food Supplements in Healthy Subjects

Role: lead

NCT02373176Phase 1Completed

[14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study

Role: lead

NCT02367937Phase 1Completed

PRC-4016 (Icosabutate) Phase I Drug-drug Interaction Study

Role: lead

NCT01422317Phase 3Completed

Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction

Role: collaborator

NCT00251134Phase 3Completed

OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction

Role: collaborator

NCT00296153Phase 4Completed

Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment

Role: lead

NCT00257283Phase 4Completed

Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis

Role: lead